Apimeds shares surge 30.77% after-hours following FDA Type C meeting for LT-100, advancing non-opioid OA treatment development.

Apimeds Pharmaceuticals US surged 30.77% in after-hours trading following the announcement of a scheduled FDA Type C meeting for LT-100 (Apitox), a non-opioid biologic candidate for osteoarthritis. The teleconference on May 4, 2026, marks a critical step in aligning with the FDA on U.S. development strategies for the therapy, which has prior approval in South Korea. The company emphasized progress in manufacturing enhancements and integrating historical data with modern standards, positioning LT-100 for potential clinical advancement. Executive statements highlighted the product’s therapeutic potential and the importance of regulatory engagement, reinforcing investor optimism about the pipeline’s future. The news directly correlates with the stock’s sharp after-hours increase.